Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Sanofi
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 19 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Jul 2014 Planned End Date changed from 1 Jan 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov.